GHP Investment Advisors’s Celldex Therapeutics CLDX Stock Holding History

GHP Investment Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$112	Sell	3 -22	-88%	-$711	﹤0.01%	1262
2026 Q1	$793	Hold	25	–	–	﹤0.01%	1062
2025 Q4	$679	Buy	+25	New	+$658	﹤0.01%	931
2023 Q2	–	Sell	-4	Closed	-$144	–	932
2023 Q1	$144	Hold	4	–	–	﹤0.01%	905
2022 Q4	$178	Hold	4	–	–	﹤0.01%	910
2022 Q3	$0	Hold	4	–	–	﹤0.01%	906
2022 Q2	$0	Hold	4	–	–	﹤0.01%	942
2022 Q1	$0	Buy	+4	New	+$128	﹤0.01%	938

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GHP Investment Advisors's CLDX Position: Q2 2026 in Review

GHP Investment Advisors reduced its Celldex Therapeutics (CLDX) stake by 88% in Q2 2026, selling an estimated $711 and leaving 3 shares worth $112. The position accounts for ﹤0.01% of the portfolio, ranked #1262.

GHP Investment Advisors first reported a position in CLDX in Q1 2022 and has held it in 8 quarters since. The position peaked at $793 in Q1 2026. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

GHP Investment Advisors held 3 shares of Celldex Therapeutics worth $112 as of Q2 2026.
GHP Investment Advisors sold 22 Celldex Therapeutics shares in Q2 2026, an estimated $711.
Celldex Therapeutics made up ﹤0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #1262 holding.
GHP Investment Advisors first reported a position in Celldex Therapeutics in Q1 2022 and has held it in 8 quarters since.
GHP Investment Advisors's Celldex Therapeutics position peaked at $793 in Q1 2026.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.